It is widely known that the current discovery and development of drugs and compounds is afflicted by high rates of attrition and low levels of productivity. We believe that pre-clinical, in vitro human cell-based devices are essential elements for driving drug discovery and development into higher levels of efficiency and safety, which will ultimately be of benefit for patients and society at large.
To make this a reality, we have built up expertise in cardiac differentiation and 3D culture technologies. First, our proprietary cardiac differentiation technology based on small-molecule compounds enables the robust and efficient conversion of human iPS cells into cardiomyocytes. Second, our 3D culture technology relies on scaffolds with aligned nanofibers for the creation of human-like multi-layered and highly oriented cardiac micro-tissues.
Our expertise allows us to develop cell devices that fine-tune the unique properties of organ tissues to the right scaffold materials for refined drug responses. Such optimum cell-material combinations result in enhanced levels of cell functionality and maturation, and ultimately in a predictive and consistent SCAD-MT ™ cell platform. In particular, our cell devices exhibit remarkable benefits for contractility and longer-term chronic toxicity studies.
The SCAD-MT ™ cell platform has been specifically developed for the safety and toxicology assays and drug discovery screening markets.